NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

This study tests a treatment called NY-ESO-1-redirected T cells — a type of personalized immunotherapy where your own immune cells are engineered to recognize and attack a protein found on certain tumors — in people with advanced melanoma (skin cancer) or sarcoma (cancers of bone or soft tissue). **You may be eligible if...** - Your tumor is confirmed to have melanoma or any type of sarcoma - Your tumor tests positive for a protein called NY-ESO-1 (found in at least 50% of tumor cells) - For sarcoma: you have already tried at least one standard therapy - For melanoma: you have tried approved treatments (including immunotherapy) **You may NOT be eligible if...** - Your tumor does not express the NY-ESO-1 protein - You have not yet tried standard therapies (if required for your tumor type) - You have significant heart, lung, or immune system problems Talk to your doctor to see if this trial is right for you.